Debiopharm and Alkyon Therapeutics announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm’s proprietary AbYlink™ conjugation technology for Alkyon’s modular antibody platform directed against undisclosed tumor-associated antigens.
This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing.
“We’re intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,” expressed Frederic Levy, Chief Scientific Officer, Debiopharm. “Leveraging our innovative conjugation platform with Alkyon’s engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.”
“This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,” said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. “By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!